The Endo-Epic Study (Endometriosis Estradiol-Mediated Pain, Inflammation, and Central Sensitization Study) is designed to explore how a hormone-suppressing medication, relugolix combination-therapy (Myfembree®), may influence pelvic pain, inflammation, and sensitivity to pain in premenopausal women who have moderate-to-severe endometriosis-associated pelvic pain.
Participants in this study will take part in a 28-week research program, which includes a 24-week period of receiving relugolix combination-therapy (Myfembree®)— a medication approved by the U.S. Food and Drug Administration for the treatment of moderate-to-severe pain associated with endometriosis. Throughout the study, participants will complete a combination of in-person and virtual visits, including brief online surveys to assess symptoms, monthly urine pregnancy tests, and specialized tests such as MRI imaging and pain sensitivity (sensory) evaluations.
Through this research, investigators aim to learn more about the biological and hormonal factors that contribute to pelvic pain in endometriosis, with the hope of informing future treatment strategies and improving quality of life for those affected.
.png){kind=icon}
Includes four full-day in-person visits in Ann Arbor, MI as well as phone calls, and online surveys.
Please note that travel reimbursement is available for participants traveling long distances for the in person-visits.
.png){kind=icon}
Study evaluates relugolix combination-therapy (Myfembree®).
.png){kind=icon}
Women aged 18 - 49 who have endometriosis diagnosed by surgery, ultrasound, or MRI within the last 10 years.
.png){kind=icon}
Participants will be compensated up to $1,345 for their time and effort.
Participants will be compensated up to $1,345 for their time and effort over the course of the study. This compensation acknowledges the time spent completing study visits, participating in tests and imaging, and engaging in follow-up assessments.
All study-related care, medication, and procedures — including MRI, and laboratory evaluations — are provided at no cost to participants.
Our goal is to ensure that participation is accessible, supported, and respectful of each individual’s time and contribution to advancing women’s health research.
.png)
The study is designed to better understand how hormone suppression with relugolix combination-therapy (Myfembree®) affects pain, inflammation, and pain sensitivity in women with endometriosis-related pelvic pain.
Four in-person visits will take place in Ann Arbor, Michigan. Additional visits may occur virtually or by phone.
Relugolix CT (Myfembree®) is FDA-approved for treatment of moderate-to-severe pain associated with endometriosis. In this study, researchers are evaluating its effects on inflammation and pain sensitivity.
No. Study medication and all study tests are provided at no cost. Compensation is provided for participation.
